Back to Index
Gary Robert Lerner, MD
Associate Professor of Clinical Pediatrics (Part Time)
CHL Mail Stop 40 Off Campus Los Angeles
+1 323 361 2102


Efficacy and safety of paricalcitol in children with stages 3 to 5 chronic kidney disease. Pediatr Nephrol. 2017 Mar 22. View in: PubMed

Darbepoetin alfa for the treatment of anemia in pediatric patients with chronic kidney disease. Pediatr Nephrol. 2006 Aug; 21(8):1144-52. View in: PubMed

Experience with autogenous arteriovenous access for hemodialysis in children and adolescents. Ann Vasc Surg. 2005 Sep; 19(5):609-12. View in: PubMed

Iron therapy in the pediatric hemodialysis population. Pediatr Nephrol. 2004 Jun; 19(6):655-61. View in: PubMed

Safety and pharmacokinetics of ascending single doses of sirolimus (Rapamune, rapamycin) in pediatric patients with stable chronic renal failure undergoing dialysis. Pediatr Transplant. 2004 Apr; 8(2):151-60. View in: PubMed

Pharmacokinetics of darbepoetin alfa in pediatric patients with chronic kidney disease. Pediatr Nephrol. 2002 Nov; 17(11):933-7. View in: PubMed

Chronic dialysis in children and adolescents. The 1996 annual report of the North American Pediatric Renal Transplant Cooperative Study. Pediatr Nephrol. 1999 Jun; 13(5):404-17. View in: PubMed

Urinary tract infections in children. Pediatr Ann. 1994 Sep; 23(9):463, 466-73. View in: PubMed

Renal cortical and renal medullary necrosis in the first 3 months of life. Pediatr Nephrol. 1992 Nov; 6(6):516-8. View in: PubMed

Powered bySC CTSI